Novartis a step closer to Alcon purchase

Article

Novartis has completed the first stage of its purchase of 74 million shares of common stock of Alcon. This step maintains Nestle as the majority shareholder of Alcon, with 52% of the company's issued capital, and establishes Novartis as a minority shareholder, holding 24.85% of Alcon's shares.

Novartis has completed the first stage of its purchase of 74 million shares of common stock of Alcon. This step maintains Nestle as the majority shareholder of Alcon, with 52% of the company's issued capital, and establishes Novartis as a minority shareholder, holding 24.85% of Alcon's shares.

The announcement follows the signing, on April 6, 2008, of the initial agreement between Nestle and Novartis.

Pursuant to Novartis's purchase of Alcon shares, the Alcon board of directors has incorporated two new members - James Singh, executive vice president and chief financial office of Nestle, and Daniel Vasella, MD, chairman and chief executive officer of Novartis - taking the total number of Alcon board members up to 10.

The agreement signed by Novartis and Nestle has options (valid January 1, 2010–July 31, 2011) allowing for Novartis to purchase Nestle's shares of Alcon, giving Novartis 77% of Alcon's shares and making Novartis the majority shareholder of Alcon.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.